Detalhe da pesquisa
1.
YIV-818-A: a novel therapeutic agent in prostate cancer management through androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation, and enhancement of apalutamide, darolutamide, and enzalutamide efficacy.
Front Pharmacol
; 14: 1244655, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37860121
2.
Barcoded microbial system for high-resolution object provenance.
Science
; 368(6495): 1135-1140, 2020 06 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32499444